The relationship between the quantitative evaluation of thyroid bed uptake and the disappearance of accumulation in adjuvant radioactive iodine therapy for differentiated thyroid cancer

被引:8
|
作者
Konishi, Kenta [1 ]
Ishiba, Ryo [1 ]
Ikenohira, Tsutomu [1 ]
Asao, Tomoyuki [1 ]
Hirata, Masanori [1 ]
Ohira, Keiichi [1 ]
Komatsu, Tetsuya [1 ]
Sawada, Michifumi [2 ]
Tanahashi, Yukichi [3 ]
Goshima, Satoshi [3 ]
Magata, Yasuhiro [4 ]
Nakamura, Katsumasa [1 ]
机构
[1] Hamamatsu Univ Sch Med, Dept Radiat Oncol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
[2] Hamamatsu Univ Sch Med, Dept Radiol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
[3] Hamamatsu Univ Sch Med, Dept Diagnost Radiol & Nucl Med, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
[4] Hamamatsu Univ Sch Med, Preeminent Med Photon Educ & Res Ctr, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
关键词
Thyroid cancer; Radioactive iodine therapy; Adjuvant therapy; Quantitative evaluation; Absolute radioactivity concentration; CARCINOMA; ABLATION;
D O I
10.1007/s12149-020-01546-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective Iodine-131 (I-131) radioactive iodine therapy (RAI) after total thyroidectomy is the standard treatment for patients with differentiated thyroid cancer (DTC). We investigated the relationship between the quantitative parameters of the iodine uptake and the disappearance of the accumulation in the thyroid bed in adjuvant therapy using a 1.11 GBq or 3.70 GBq dose of I-131. Methods We retrospectively analyzed the cases of 40 patients with DTC who were treated with RAI at our institution between April 2017 and August 2019. The patients were treated with the I-131 dose of 1.11 GBq (n = 25) or 3.70 GBq (n = 15) after total thyroidectomy. The I-131 whole-body scan and hybrid single-photon emission computed tomography/X-ray computed tomography (SPECT/CT) were performed 3 days after RAI. Using image analysis software, we measured the standardized uptake value (SUV) and absolute radioactivity concentration (kBq/ml) on the target lesions with the highest uptake in the thyroid bed. Results The median period from RAI to the evaluation of the absence of uptake of the thyroid bed was 6.75 months. After RAI, uptake of the thyroid bed disappeared in 26 of the 40 patients. The disappearance rate was significantly higher in the 3.70 GBq group than in the 1.11 GBq group (86.7% vs. 52.0%, respectively; p = 0.029). However, there were no significant differences in the values of kBq/ml or SUV between the 1.11 GBq group and 3.70 GBq group. On the other hand, the group in which the uptake disappeared after RAI showed significantly higher kBq/ml max and kBq/ml mean values than the group in which the uptake did not disappear after RAI (p = 0.028, p = 0.032, respectively). The SUVmax and SUVmean also tended to be higher in the disappeared-uptake group than the not-disappeared-uptake group, but the differences were not significant (p = 0.166, p = 0.176, respectively). Conclusions The quantitative evaluation might be useful as one of the predictive indicators of the disappearance of the accumulation of radioactive iodine in the thyroid bed.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 50 条
  • [41] The Treatment of Differentiated Thyroid Cancer in Children: Emphasis on Surgical Approach and Radioactive Iodine Therapy
    Rivkees, Scott A.
    Mazzaferri, Ernest L.
    Verburg, Frederik A.
    Reiners, Christoph
    Luster, Markus
    Breuer, Christopher K.
    Dinauer, Catherine A.
    Udelsman, Robert
    ENDOCRINE REVIEWS, 2011, 32 (06) : 798 - 826
  • [42] Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer
    D. P. Momesso
    F. Vaisman
    L. S. C. Caminha
    C. H. C. N. Pessoa
    R. Corbo
    M. Vaisman
    Journal of Endocrinological Investigation, 2014, 37 : 57 - 64
  • [43] Low-iodine diet in the treatment of differentiated thyroid cancer with radioactive iodine
    Martin Sonenberg
    Endocrine, 2002, 17 : 141 - 143
  • [44] Low-iodine diet in the treatment of differentiated thyroid cancer with radioactive iodine
    Sonenberg, M
    ENDOCRINE, 2002, 17 (02) : 141 - 143
  • [45] Feasibility of a randomized trial on adjuvant radio-iodine therapy in differentiated thyroid cancer
    Dragoiescu, C
    Hoekstra, OS
    Kuik, DJ
    Lips, P
    Plaizier, MABD
    Rodrigus, PTR
    Huijsmans, DAKCJM
    Ribot, JG
    Kuijpens, J
    Coebergh, JWW
    Teule, GJJ
    CLINICAL ENDOCRINOLOGY, 2003, 58 (04) : 451 - 455
  • [46] Effects of thyroid hormone withdrawal on natriuretic peptides during radioactive iodine therapy in female patients with differentiated thyroid cancer
    Stanciu, Adina Elena
    Hurduc, Anca Elena
    Stanciu, Marcel Marian
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2016, 76 (08): : 626 - 631
  • [49] Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome
    Lukovic, Jelena
    Petrovic, Irina
    Liu, Zijin
    Armstrong, Susan M.
    Brierley, James D.
    Tsang, Richard
    Pasternak, Jesse D.
    Gomez-Hernandez, Karen
    Liu, Amy
    Asa, Sylvia L.
    Mete, Ozgur
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [50] EFFECT OF RADIOACTIVE IODINE DOSING ON DISEASE RECURRENCE IN DIFFERENTIATED THYROID CANCER
    Baker, Sarah
    Zenke, Julianna
    McMullen, Todd
    Morad, Ahmed
    Chao, Ma
    Williams, David
    Capelle, Lisa
    Severin, Diane
    Morrish, Don
    McEwan, Ajb
    Ghosh, Sunita
    Chu, Karen P.
    RADIOTHERAPY AND ONCOLOGY, 2016, 120 : S80 - S80